Amand F Schmidt

List of Publications by Year in Descending Order

62 papers	1,585 citations	15 h-index	39 g-index
79 ext. papers	2,306 ext. citations	7.1 avg, IF	4.68 L-index

#	Paper	IF	Citations
62	Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settings.. *Diabetologia*, **2022**, 65, 644	10.3	1
61	Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. *Heart*, **2022**, 108, 14-15	5.1	
60	Unravelling the Difference Between Men and Women in Post-CABG Survival.. *Frontiers in Cardiovascular Medicine*, **2022**, 9, 768972	5.4	0
59	Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. *Nature Communications*, **2021**, 12, 5640	17.4	7
58	Human Genomics and Drug Development. *Cold Spring Harbor Perspectives in Medicine*, **2021**,	5.4	2
57	Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics. *Nature Communications*, **2021**, 12, 6120	17.4	2
56	Dementia in the older population is associated with neocortex content of serum amyloid P component. *Brain Communications*, **2021**, 3, fcab225	4.5	2
55	Establishing reference intervals for triglyceride-containing lipoprotein subfraction metabolites measured using nuclear magnetic resonance spectroscopy in a UK population. *Annals of Clinical Biochemistry*, **2021**, 58, 47-53	2.2	0
54	Risk Factors and Prevalence of Dilated Cardiomyopathy in Sub-Saharan Africa: Protocol for a Systematic Review. *JMIR Research Protocols*, **2021**, 10, e18229	2	1
53	Mendelian randomization for studying the effects of perturbing drug targets. *Wellcome Open Research*, **2021**, 6, 16	4.8	15
52	No Clinically Relevant Effect of Heart Rate Increase and Heart Rate Recovery During Exercise on Cardiovascular Disease: A Mendelian Randomization Analysis. *Frontiers in Genetics*, **2021**, 12, 569323	4.5	2
51	Mendelian randomization for studying the effects of perturbing drug targets. *Wellcome Open Research*, **2021**, 6, 16	4.8	11
50	Circulating Fatty Acids and Risk of Coronary Heart Disease and Stroke: Individual Participant Data Meta-Analysis in Up to 16□126 Participants. *Journal of the American Heart Association*, **2020**, 9, e013131	6	13
49	Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia. *British Journal of Clinical Pharmacology*, **2020**, 86, 1827-1835	3.8	6
48	Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients. *Frontiers in Psychiatry*, **2020**, 11, 38	5	7
47	Genetic drug target validation using Mendelian randomisation. *Nature Communications*, **2020**, 11, 3255	17.4	34
46	The median and the mode as robust meta-analysis estimators in the presence of small-study effects and outliers. *Research Synthesis Methods*, **2020**, 11, 397-412	7.2	8

45	Triglyceride-containing lipoprotein sub-fractions and risk of coronary heart disease and stroke: A prospective analysis in 11,560 adults. *European Journal of Preventive Cardiology*, **2020**, 27, 1617-1626	3.9	9
44	Obesity causes cardiovascular diseases: adding to the weight of evidence. *European Heart Journal*, **2020**, 41, 227-230	9.5	10
43	Lipid lowering and Alzheimer disease risk: A mendelian randomization study. *Annals of Neurology*, **2020**, 87, 30-39	9.4	20
42	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. *The Cochrane Library*, **2020**, 10, CD011748	5.2	12
41	Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data. *Circulation*, **2020**, 142, 546-555	16.7	5
40	Establishing reference intervals for triglyceride containing lipoprotein sub-fraction metabolites measured using nuclear magnetic resonance spectroscopy in a UK population. *Atherosclerosis*, **2020**, 315, e95-e96	3.1	
39	Polygenic risk scores for coronary artery disease and subsequent event risk amongst established cases. *Human Molecular Genetics*, **2020**, 29, 1388-1395	5.6	8
38	When drug treatments bias genetic studies: Mediation and interaction. *PLoS ONE*, **2019**, 14, e0221209	3.7	0
37	Associations Between Measures of Sarcopenic Obesity and Risk of Cardiovascular Disease and Mortality: A Cohort Study and Mendelian Randomization Analysis Using the UK Biobank. *Journal of the American Heart Association*, **2019**, 8, e011638	6	37
36	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002470	5.2	13
35	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002471	5.2	14
34	Adjustment for index event bias in genome-wide association studies of subsequent events. *Nature Communications*, **2019**, 10, 1561	17.4	38
33	Long-term incidence and risk factors of cardiovascular events in Asian populations: systematic review and meta-analysis of population-based cohort studies. *Current Medical Research and Opinion*, **2019**, 35, 291-299	2.5	7
32	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. *BMC Cardiovascular Disorders*, **2019**, 19, 240	2.3	8
31	An electronic health records cohort study on heart failure following myocardial infarction in England: incidence and predictors. *BMJ Open*, **2018**, 8, e018331	3	21
30	Linear regression and the normality assumption. *Journal of Clinical Epidemiology*, **2018**, 98, 146-151	5.7	144
29	Mendelian randomization with Egger pleiotropy correction and weakly informative Bayesian priors. *International Journal of Epidemiology*, **2018**, 47, 1217-1228	7.8	11
28	Adjusting for bias in unblinded randomized controlled trials. *Statistical Methods in Medical Research*, **2018**, 27, 2413-2427	2.3	3

27	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. *The Cochrane Library*, **2017**, 4, CD011748	5.2	57
26	PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 97-105	18.1	225
25	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 534-543	18.1	69
24	Impact of Selection Bias on Estimation of Subsequent Event Risk. *Circulation: Cardiovascular Genetics*, **2017**, 10,		19
23	Association analyses based on false discovery rate implicate new loci for coronary artery disease. *Nature Genetics*, **2017**, 49, 1385-1391	36.3	361
22	Adjusting for Confounding in Early Postlaunch Settings: Going Beyond Logistic Regression Models. *Epidemiology*, **2016**, 27, 133-42	3.1	10
21	Re: Is the Risk Difference Really a More Heterogeneous Measure?. *Epidemiology*, **2016**, 27, e12	3.1	6
20	Tailoring treatments using treatment effect modification. *Pharmacoepidemiology and Drug Safety*, **2016**, 25, 355-62	2.6	8
19	Which dogs with appendicular osteosarcoma benefit most from chemotherapy after surgery? Results from an individual patient data meta-analysis. *Preventive Veterinary Medicine*, **2016**, 125, 116-25	3.1	6
18	Chemotherapy effectiveness and mortality prediction in surgically treated osteosarcoma dogs: A validation study. *Preventive Veterinary Medicine*, **2016**, 125, 126-34	3.1	2
17	Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis. *PLoS Medicine*, **2016**, 13, e1002179	11.6	214
16	Comparison of variance estimators for meta-analysis of instrumental variable estimates. *International Journal of Epidemiology*, **2016**, 45, 1975-1986	7.8	3
15	Bayesian methods including nonrandomized study data increased the efficiency of postlaunch RCTs. *Journal of Clinical Epidemiology*, **2015**, 68, 387-96	5.7	3
14	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease **2015**,		4
13	Comments on The use of propensity scores and observational data to estimate randomized controlled trial generalizability biasTby Taylor R. Pressler and Eloise E. Kaizar, Statistics in Medicine 2013. *Statistics in Medicine*, **2014**, 33, 536-7	2.3	5
12	Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: results from a systematic review and simulation study. *Journal of Clinical Epidemiology*, **2014**, 67, 821-9	5.7	35
11	Justification of exclusion criteria was underreported in a review of cardiovascular trials. *Journal of Clinical Epidemiology*, **2014**, 67, 635-44	5.7	20
10	Prognostic factors of early metastasis and mortality in dogs with appendicular osteosarcoma after receiving surgery: an individual patient data meta-analysis. *Preventive Veterinary Medicine*, **2013**, 112, 414-22	3.1	35

9	Differences in interaction and subgroup-specific effects were observed between randomized and nonrandomized studies in three empirical examples. *Journal of Clinical Epidemiology*, **2013**, 66, 599-607	5.7	10
8	Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care setting		1
7	Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics		1
6	Association of polygenic risk scores for coronary artery disease with subsequent events amongst established cases		2
5	Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular Disease		1
4	The median and the mode as robust meta-analysis methods in the presence of small study effects		1
3	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9		1
2	Adjustment for index event bias in genome-wide association studies of subsequent events		1
1	Genetic drug target validation using Mendelian randomization		4